RHRoa’a Hamed

Roa’a Hamed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roa’a Hamed has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Folate transfer across the placenta during late pregnancy in women with epilepsy: A cross‐sectional, two‐center study

    by Erez Berman, Gali Pariente, Natalia Erenburg, Roa’A Hamed, Cecilie Johannessen Landmark, Michal Kovo, Sara Eyal

    Objective: In women with epilepsy who are treated with antiseizure medications (ASMs), folate concentrations in maternal serum may not be a good indicator of fetal folate supply, because ASMs can interfere with folate handling by the placenta. We aimed to assess the transplacental folate transfer at birth in persons with epilepsy in comparison to controls with no known epilepsy and identify factors affecting it. Methods: This was a cross‐sectional, two‐center study, involving 22 pregnant women with epilepsy treated with ASMs, 10 nontreated pregnant women with epilepsy, and 19 control pregnant individuals with no known epilepsy. Maternal venous blood and umbilical cord blood samples were collected at delivery. Folate concentrations were measured using a validated chemiluminescence assay. ASM concentrations were analyzed in serum and umbilical cord blood. Results: Maternal and neonatal characteristics were generally comparable across the study groups, but cesarian sections were more frequent among controls ( p < .001). Folate concentrations in maternal serum were lower than recommended levels in nine of 26 (35%) of women with epilepsy and eight of 19 (42%) controls. Median cord/maternal serum folate ratios were 1.51 (95% confidence interval [CI] = .92–6.35; n = 17) in women with epilepsy treated with ASMs and 2.02 (95% CI = 1.69–3.71; n = 19) in controls. In women with epilepsy, placental folate transfer was saturable (Cmax = 131.1 ng/mL, 95% CI = 96.4–190.5 ng/mL; Michaelis‐Menten constant, Km = 32.6 ng/mL, 95% CI = 12.5–76.9 ng/mL; adjusted R 2 = .70). Predictability of cord values improved upon exclusion of preterm births (Cmax = 125.2 ng/mL, 95% CI = 97.4–164.7 ng/mL; Km =41.1 ng/mL, 95% CI = 22.4–71.1 ng/mL; adjusted R 2 = .78). Significance: Folate delivery to the fetus during late pregnancy is primarily explained by its concentrations in maternal circulation. In persons with epilepsy, it may be saturable. The frequent apparent folate deficiency observed in our cohort highlights the importance of folate supplementation and monitoring of its levels in maternal circulation throughout pregnancy.


  • Open Access

    Folate transfer in placental choriocarcinoma cells treated with valproic acid: Insights gained through comparisons with the amide derivative sec‐butylpropylacetamide and its individual stereoisomers

    by Natalia Erenburg, Roa’a Hamed, Alina Nemirovski, Meir Bialer, Sara Eyal

    Objective: We have previously shown that valproic acid (VPA) alters the expression of placental carriers of essential nutrients, including folates. Here, we exposed a placental cell line to VPA, its central nervous system‐active amide derivative sec‐butylpropylacetamide (SPD), and its individual stereoisomers to address the question of whether folate carrier expression can predict the teratogenicity of VPA‐related compounds. We additionally conducted a pilot analysis of folate transfer across placental cell monolayers to estimate the translation of altered carrier expression to carrier activity.Methods: BeWo cells were incubated for 2 or 5 days with racemic SPD, its stereoisomers (2S,3S)‐SPD, (2R,3S)‐SPD, and (2R,3R)‐SPD (previously found to be teratogenic at high doses in mice; .5 or 1 mmol·L−1), VPA (1 mmol·L−1 = 144 mg/L), or their vehicle. Expression of FOLR1 (folate receptor alpha), SLC19A1 (reduced folate carrier), and ABCG2 (breast cancer resistance protein) was measured by real‐time polymerase chain reaction. Folate transfer across monolayers of BeWo b30 cells exposed to .5 mmol·L−1 (2R,3R)‐SPD or 1 mmol·L−1 VPA was quantified by liquid chromatography–mass spectrometry analysis.Results: At 1 mmol·L−1, racemic SPD, (2S,3S)‐SPD, and (2R,3S)‐SPD reduced by twofold SLC19A1 expression, similar to VPA (p < .001). SPD and its enantiomers induced FOLR1 expression by up to twofold (p < .05) or did not significantly affect it, and racemic SPD increased ABCG2 expression (p < .01). After 5 days, VPA, but not (2R,3R)‐SPD, enhanced both maternal‐to‐fetal and fetal‐to‐maternal folate transfer (p < .01), resulting in a 15% increase in net transfer in the fetal direction.Significance: Altered expression of the studied carriers could not explain the folate transfer kinetics across placental cell monolayers. Future studies should assess the effects of VPA and other antiseizure medications on transplacental transfer of essential compounds in vivo and the ability to predict it by functional in vitro assays.


  • Open Access

    Differential Effect of Simulated Microgravity on the Cellular Uptake of Small Molecules

    by Odelia Tepper-Shimshon, Nino Tetro, Roa’a Hamed, Natalia Erenburg, Emmanuelle Merquiol, Gourab Dey, Agam Haim, Tali Dee, Noa Duvdevani, Talin Kevorkian, et al.

    The space environment can affect the function of all physiological systems, including the properties of cell membranes. Our goal in this study was to explore the effect of simulated microgravity (SMG) on the cellular uptake of small molecules based on reported microgravity-induced changes in membrane properties. SMG was applied to cultured cells using a random-positioning machine for up to three hours. We assessed the cellular accumulation of compounds representing substrates of uptake and efflux transporters, and of compounds not shown to be transported by membrane carriers. Exposure to SMG led to an increase of up to 60% (p < 0.01) in the cellular uptake of efflux transporter substrates, whereas a glucose transporter substrate showed a decrease of 20% (p < 0.05). The uptake of the cathepsin activity-based probe GB123 (MW, 1198 g/mol) was also enhanced (1.3-fold, p < 0.05). Cellular emission of molecules larger than ~3000 g/mol was reduced by up to 50% in SMG (p < 0.05). Our findings suggest that short-term exposure to SMG could differentially affect drug distribution across membranes. Longer exposure to microgravity, e.g., during spaceflight, may have distinct effects on the cellular uptake of small molecules.


  • Open Access

    Identifying genetic susceptibility to Aspergillus fumigatus infection using collaborative cross mice and RNA‐Seq approach

    by Roa'A H. S. Yosief, Iqbal M. Lone, Aharon Nachshon, Heinz Himmelbauer, Irit Gat‐Viks, Fuad A. Iraqi

    Background: Aspergillus fumigatus (Af) is one of the most ubiquitous fungi and its infection potency is suggested to be strongly controlled by the host genetic background. The aim of this study was to search for candidate genes associated with host susceptibility to Aspergillus fumigatus (Af) using an RNAseq approach in CC lines and hepatic gene expression. Methods: We studied 31 male mice from 25 CC lines at 8 weeks old; the mice were infected with Af. Liver tissues were extracted from these mice 5 days post-infection, and next-generation RNA-sequencing (RNAseq) was performed. The GENE-E analysis platform was used to generate a clustered heat map matrix. Results: Significant variation in body weight changes between CC lines was observed. Hepatic gene expression revealed 12 top prioritized candidate genes differentially expressed in resistant versus susceptible mice based on body weight changes. Interestingly, three candidate genes are located within genomic intervals of the previously mapped quantitative trait loci (QTL), including Gm16270 and Stox1 on chromosome 10 and Gm11033 on chromosome 8. Conclusions: Our findings emphasize the CC mouse model's power in fine mapping the genetic components underlying susceptibility towards Af. As a next step, eQTL analysis will be performed for our RNA-Seq data. Suggested candidate genes from our study will be further assessed with a human cohort with aspergillosis.


  • Pharmacokinetics of d‐ and l‐norfenfluramine following their administration as individual enantiomers in rats

    by Natalia Erenburg, Roa'A Hamed, Chanan Shaul, Dinorah Barasch, Emilio Perucca, Meir Bialer

    The effect of fenfluramine and norfenfluramine enantiomers in rodent seizure models and their correlation with the pharmacokinetics of d- and l-fenfluramine in rats have been reported recently. To complement these findings, we investigated the pharmacokinetics of d- and l- norfenfluramine in rat plasma and brain. Sprague-Dawley rats were injected intraperitoneally with 20 mg/kg and 1 mg/kg l- norfenfluramine. A 1 mg/kg dose of d-norfenfluramine was used because higher doses caused severe toxicity. The concentration of each enantiomer in plasma and brain was determined at different time points by liquid chromatography/mass spectrometry. Pharmacokinetic parameters were compared between norfenfluramine enantiomers, and with those reported previously for fenfluramine enantiomers after a 20 mg/kg, i.p., dose. All enantiomers were absorbed rapidly and eliminated, with half-lives ranging from 0.9 h (l-fenfluramine) to 6.1 h (l- norfenfluramine, 20 mg/kg) in plasma, and from 3.6 h (d-fenfluramine) to 8.0 h (l-fenfluramine) in brain. Brain-to-plasma concentration ratios ranged from 15.4 (d-fenfluramine) to 27.6 (d-norfenfluramine), indicating extensive brain penetration. The fraction of d- and l-fenfluramine metabolized to norfenfluramine was estimated to be close to unity. This work is part of ongoing investigations to determine the potential value of developing enantiomerically pure l-fenfluramine or l-norfenfluramine as follow-up compounds to the marketed racemic fenfluramine.


  • Open Access

    In silico screening for clinical efficacy of antiseizure medications: Not all central nervous system drugs are alike

    by Roaa Hamed, Amit David Eyal, Erez Berman, Sara Eyal